The invention belongs to the field of biomedicine, and particularly relates to use of lecithin-cholesterol acyltransferase (LCAT) in preparing a drug or a healthcare product for treating and / or preventing the hepatic bone disease. According to the cell and animal experiments, the LCAT can realize reverse cholesterol transport of from osteocyte to hepatocyte, so that osteoporosis is relieved; meanwhile, an abnormal skeletal system in a chronic cirrhosis process further can be relieved, and bone density is increased, so that a brand-new choice and idea is provided for treating chronic hepatic bone disease, and the LCAT has a potential clinical application prospect.